Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Upsala journal of medical sciences - 1 Jan 2024

Falkman Lovisa, Sundin Anders, Skogseid Britt, Botling Johan, Bernardo Yvette, Wallin Göran, Zhang Liang, Welin Staffan, Lase Ieva, Mollazadegan Kazhan, Crona Joakim

Abstract excerpt

Background: Metastatic neuroendocrine carcinoma (NEC) is associated with short survival. Other than platinum-based chemotherapy, there is no clear standard regimen. Current guidelines suggest that combination treatment with BRAF-inhibitors should be considered for patients with BRAF V600E-mutated NEC. However, since only eight such patients have been reported in the literature, our object was to confirm the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Oximes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 38716076
DOI: 10.48101/ujms.v129.10660
PMCID: PMC11075439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.PMID 38716076Read ↗

Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.Semantic proximity Read ↗

Evaluation of therapeutic agent selection based on comprehensive genomic profiling in gastroenteropancreatic neuroendocrine neoplasmsSemantic proximity Read ↗

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.Semantic proximity Read ↗

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Semantic proximity Read ↗

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.Semantic proximity Read ↗

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.Semantic proximity Read ↗

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.Semantic proximity Read ↗

Genetic mutations in neuroendocrine carcinomas of unknown primary.Semantic proximity Read ↗

Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.Semantic proximity Read ↗

In-depth analysis of the genomic landscape of 86 metastatic neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targetsSemantic proximity Read ↗

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Semantic proximity Read ↗

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.